Quantum Cyber N.V.

NasdaqCM:QUCY Stock Report

Market Cap: US$26.5m

Quantum Cyber Valuation

Is QUCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of QUCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate QUCY's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate QUCY's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QUCY?

Key metric: As QUCY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for QUCY. This is calculated by dividing QUCY's market cap by their current revenue.
What is QUCY's PS Ratio?
PS Ratio45.2x
SalesUS$537.08k
Market CapUS$26.53m

Price to Sales Ratio vs Peers

How does QUCY's PS Ratio compare to its peers?

The above table shows the PS ratio for QUCY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.8x
CRVO CervoMed
20x70.17%US$23.0m
CRIS Curis
2.2x47.10%US$15.7m
MRKR Marker Therapeutics
6.3x64.28%US$22.5m
BTAI BioXcel Therapeutics
54.5x61.13%US$37.1m
QUCY Quantum Cyber
45.2x-66.89%US$26.5m

Price-To-Sales vs Peers: QUCY is expensive based on its Price-To-Sales Ratio (45.2x) compared to the peer average (20.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does QUCY's PS Ratio compare vs other companies in the US Biotechs Industry?

126 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.9x2.53%US$28.88b
INCY Incyte
3.7x-1.12%US$19.93b
BMRN BioMarin Pharmaceutical
3.3x10.07%US$10.65b
ACAD ACADIA Pharmaceuticals
3.3x10.08%US$3.59b
QUCY 45.2xIndustry Avg. 10.3xNo. of Companies126PS01632486480+
126 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: QUCY is expensive based on its Price-To-Sales Ratio (45.2x) compared to the US Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is QUCY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QUCY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio45.2x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: QUCY is expensive based on its Price-To-Sales Ratio (45.2x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

US$14
Fair Value
86.1% undervalued intrinsic discount
0
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 16:25
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quantum Cyber N.V. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael OkunewitchMaxim Group